Moleculin Receives Approval from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) for Protocol Modification to Part 1a Scientific Trial of WP1122 for the Remedy of COVID-19
– Dosing for first-in-human Part 1a research to judge security and pharmacokinetics of WP1122 in wholesome volunteers and set up most tolerated dose anticipated to start imminently – HOUSTON, Could 10, 2022 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Firm”), a medical stage pharmaceutical firm with a broad portfolio of drug candidates…